The Risk of Cancer Among Insulin Glargine Users in Lithuania: A Retrospective Population-based Study

Overview

Journal Open Med (Wars)

Specialty General Medicine

Date 2024 Oct 22

PMID 39434861

Authors

Justinas Jonusas

Mingaile Drevinskaite

Donata Linkeviciute-Ulinskiene

Adomas Ladukas

Ausvydas Patasius

Lina Zabuliene

Giedre Smailyte

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of this study was to determine the association between insulin glargine usage and the potential increase in cancer risk among the Lithuanian population diagnosed with type 2 diabetes mellitus (T2DM).

Methods: A retrospective cohort study was conducted. The cohort of insulin users was established by identifying all male and female patients diagnosed with T2DM, as recorded in the National Health Insurance Fund database between 1 January 2000 and 31 December 2012. The risk of cancer among insulin glargine users was compared with the risk in non-glargine insulin users. Cox proportional hazard models were used to estimate hazard ratios (HR) and their 95% confidence intervals (CI).

Results: The overall cancer risk for all sites combined showed no significant difference (HR 0.84, 95% CI 0.67-1.05). Although a general decrease in the risk of cancers was observed at most sites for glargine users, the use of insulin glargine was associated with a non-significant increase in the risk of mouth and pharynx, stomach, non-melanoma skin, breast, cervical, ovarian, and central nervous system cancers. There was a tendency for a lower risk of colon, rectum, rectosigmoid, and anus cancer among glargine users (HR 0.45, 95% CI 0.18-1.12, = 0.09).

Conclusions: Our research contributes to the growing body of evidence showing that insulin glargine is not associated with an increased risk of all cancers or specific types of cancer.

References

Mardilovich K, Pankratz S, Shaw L . Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal. 2009; 7:14. PMC: 2709114. DOI: 10.1186/1478-811X-7-14. View

Jonasson J, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G . Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009; 52(9):1745-54. DOI: 10.1007/s00125-009-1444-2. View

Linkeviciute-Ulinskiene D, Patasius A, Zabuliene L, Stukas R, Smailyte G . Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study. Int J Environ Res Public Health. 2020; 17(1). PMC: 6982113. DOI: 10.3390/ijerph17010246. View

. Standards of medical care in diabetes--2011. Diabetes Care. 2011; 34 Suppl 1:S11-61. PMC: 3006050. DOI: 10.2337/dc11-S011. View

Khan M, Hashim M, King J, Govender R, Mustafa H, Al Kaabi J . Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020; 10(1):107-111. PMC: 7310804. DOI: 10.2991/jegh.k.191028.001. View

Peeters P, Bazelier M, Leufkens H, Auvinen A, van Staa T, de Vries F . Insulin glargine use and breast cancer risk: Associations with cumulative exposure. Acta Oncol. 2016; 55(7):851-8. PMC: 4975082. DOI: 10.3109/0284186X.2016.1155736. View

. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016; 387(10027):1513-1530. PMC: 5081106. DOI: 10.1016/S0140-6736(16)00618-8. View

Gallagher E, LeRoith D . Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care. 2013; 36 Suppl 2:S233-9. PMC: 3920794. DOI: 10.2337/dcS13-2001. View

Currie C, Poole C, Gale E . The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52(9):1766-77. DOI: 10.1007/s00125-009-1440-6. View

10.

Holman N, Young B, Gadsby R . Current prevalence of Type 1 and Type 2 diabetes in adults and children in the UK. Diabet Med. 2015; 32(9):1119-20. DOI: 10.1111/dme.12791. View

11.

Gallagher E, Zelenko Z, Tobin-Hess A, Werner U, Tennagels N, LeRoith D . Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes. Diabetologia. 2016; 59(9):2018-25. PMC: 4970885. DOI: 10.1007/s00125-016-4000-x. View

12.

Cheraghpour M, Askari M, Tierling S, Shojaee S, Sadeghi A, Moghadam P . A systematic review and meta-analysis for the association of the insulin-like growth factor1 pathway genetic polymorphisms with colorectal cancer susceptibility. Front Oncol. 2023; 13:1168942. PMC: 10240407. DOI: 10.3389/fonc.2023.1168942. View

13.

Tsilidis K, Kasimis J, Lopez D, Ntzani E, Ioannidis J . Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015; 350:g7607. DOI: 10.1136/bmj.g7607. View

14.

Ahmad I, Suhail M, Ahmad A, Alhosin M, Tabrez S . Interlinking of diabetes mellitus and cancer: An overview. Cell Biochem Funct. 2023; 41(5):506-516. DOI: 10.1002/cbf.3802. View

15.

Rendell M, Akturk H, Tella S . Glargine safety, diabetes and cancer. Expert Opin Drug Saf. 2013; 12(2):247-63. DOI: 10.1517/14740338.2013.770469. View

16.

Vitale E, Rizzo A, Santa K, Jirillo E . Associations between "Cancer Risk", "Inflammation" and "Metabolic Syndrome": A Scoping Review. Biology (Basel). 2024; 13(5). PMC: 11117847. DOI: 10.3390/biology13050352. View

17.

Panigrahi G, Candia J, Dorsey T, Tang W, Ohara Y, Byun J . Diabetes-associated breast cancer is molecularly distinct and shows a DNA damage repair deficiency. JCI Insight. 2023; 8(23). PMC: 10795835. DOI: 10.1172/jci.insight.170105. View

18.

Bradley M, Chillarige Y, Lee H, Wu X, Parulekar S, Wernecke M . Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins. Diabetes Care. 2020; 43(4):785-792. DOI: 10.2337/dc19-0614. View

19.

Blonde L, Umpierrez G, Reddy S, McGill J, Berga S, Bush M . American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022; 28(10):923-1049. PMC: 10200071. DOI: 10.1016/j.eprac.2022.08.002. View

20.

. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2024. Diabetes Care. 2023; 47(Suppl 1):S52-S76. PMC: 10725809. DOI: 10.2337/dc24-S004. View